» Articles » PMID: 35192545

Stromal Oncostatin M Cytokine Promotes Breast Cancer Progression by Reprogramming the Tumor Microenvironment

Abstract

The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.

Citing Articles

Cytokine-centered strategies to boost cancer immunotherapy.

Manzano S, Caffarel M Mol Oncol. 2025; 19(3):579-583.

PMID: 39918251 PMC: 11887662. DOI: 10.1002/1878-0261.13818.


Nanoparticles Modulating the Immune Microenvironment in Breast Cancer Treatment.

Guo L, Wu J, Lu W, Li J, Wang Y, Yang H Int J Nanomedicine. 2025; 20:1367-1382.

PMID: 39917056 PMC: 11799854. DOI: 10.2147/IJN.S492713.


The therapeutic potential of targeting Oncostatin M and the interleukin-6 family in retinal diseases: A comprehensive review.

Mori T, Nagaraj N, Surico P, Zhou W, Parmar U, DEsposito F Open Life Sci. 2025; 19(1):20221023.

PMID: 39759107 PMC: 11699559. DOI: 10.1515/biol-2022-1023.


β-Catenin mediated TAM phenotype promotes pancreatic cancer metastasis via the OSM/STAT3/LOXL2 axis.

Zhang Y, Zhu X, Chen L, Gao T, Chen G, Zhu J Neoplasia. 2024; 60:101096.

PMID: 39740539 PMC: 11745814. DOI: 10.1016/j.neo.2024.101096.


Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.

Chernosky N, Tamagno I, Polak K, Ricky Chan E, Yuan X, Jackson M Breast Cancer Res. 2024; 26(1):167.

PMID: 39593161 PMC: 11590466. DOI: 10.1186/s13058-024-01918-2.


References
1.
Kan C, Cipriano R, Jackson M . c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M. Cancer Res. 2011; 71(22):6930-9. PMC: 4116142. DOI: 10.1158/0008-5472.CAN-10-3860. View

2.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

3.
Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F . Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res. 2012; 18(11):3054-70. DOI: 10.1158/1078-0432.CCR-11-1078. View

4.
Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View

5.
Aran D, Hu Z, Butte A . xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017; 18(1):220. PMC: 5688663. DOI: 10.1186/s13059-017-1349-1. View